New Treatment Options for COPD

Lecture presented by Dr. Antonio Anzueto (USA), a highly respected authority in pulmonary medicine and critical care at the Pulomanry Medicine Update Conference organized by the Pulmonary Critical Care Working Group on November 20, 2025,  at Kasr Al Ainy Hospital, Cairo, Egypt.This one-day intensive conference brougt together leading international experts and Egyptian specialists to share the latest advances in Pulmonary Medicine .

This presentation covers the latest advances in COPD management, including updates to the GOLD 2026 guidelines and emerging therapies.

---

GOLD 2026 Guidelines Update

• • Group A (diagnosis only): Long-acting bronchodilators
  • Group B (symptomatic): Fixed LABA/LAMA combinations
  • Group E (exacerbators): Now redefined — even one moderate exacerbation qualifies a patient for this high-risk group, triggering escalation to triple therapy

The Problem Triple Therapy Hasn’t Solved

Despite triple therapy achieving a 26% reduction in exacerbations and 30% reduction in all-cause mortality, 49–62% of patients still exacerbate. These patients are severely ill, oxygen-dependent, and heavily exposed to systemic steroids (~73 days/year on average). Yet 73% of providers believe their patients are “fine.”

---

New Molecules on the Horizon

1. Ensifentrine (PDE3/PDE4 inhibitor)

• • Triple action: bronchodilator + anti-inflammatory + mucolytic
  • Enhances CFTR activation and ciliary function to improve mucus clearance
  • Phase 3 trials (ENHANCE 1 & 2) showed improved lung function, symptom relief, and reduced exacerbations — with no GI side effects (unlike older PDE4 inhibitors like roflumilast)
  • Now included in GOLD 2026 as an add-on for symptomatic patients on LABA/LAMA

2. Dupilumab (anti-IL-4/IL-13 biologic)

• • Phase 3 trials (BOREAS & NOTUS) in patients on triple therapy with ≥300 eosinophils and chronic bronchitis
  • 30% reduction in exacerbations, less need for systemic steroids and antibiotics
  • +50 mL improvement in lung function on top of bronchodilator gains
  • Approved by FDA and EMA; effective regardless of smoking status

3. Mepolizumab (anti-IL-5 biologic)

• • Phase 3 trial showed significant reduction in exacerbations, benefit seen even at eosinophil counts ≥150
  • Lung function benefit emerged after ~76 weeks
  • Important safety note: shingles vaccine is recommended for all COPD patients on biologics

---

Why Some Biologics Are Failing in Phase 3

Three recent programs (benralizumab, itepekimab, astegolimab) had negative phase 3 trials. A key reason: the control group’s exacerbation rate has dropped dramatically over the years (from 1.71 in 2015–17 to 1.01 in 2021–24), making it harder to show added benefit — a testament to how much optimized bronchodilator therapy has already improved outcomes.

---

Key Takeaway

COPD is not asthma. Biological mechanisms differ — for example, dupilumab does not reduce eosinophils in COPD the way it does in asthma. The future lies in combining bronchodilators, novel anti-inflammatory/mucolytic agents like ensifentrine, and targeted biologics to tackle the remaining burden of exacerbations, mucus plugging, and disease progression.